Covid-19NCT04849611
Covid-19 Fear and Compliance With Protective Measures of Students
An observational study of Covid-19, run by Ordu University at 1 site in Turkey (Türkiye).
Trial summary
This study was carried out to determine the fear of Covid-19 and the compliance with protective measures of students who continue their education face-to-face during the covid-19 pandemic process. Read more about this study
- Who is it for?
- Ages 12 to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Covid-19
- How many people
- 188 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 12 Nov 2020to 1 May 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: continued face-to-face education students
Who may be able to join
- Students who volunteered to participate in the study, had their parents' consent, had a web-based smart device, and continued face-to-face education were included.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Covid-19 Fear and Compliance With Protective Measures of Students Continuing Face-to-Face Education in the Covid-19 Pandemic Process
This study was carried out to determine the fear of Covid-19 and the compliance with protective measures of students who continue their education face-to-face during the covid-19 pandemic process.
Read the detailed description
The study was carried out descriptively. The study population of a province pandemic period junior ongoing training to face in Turkey. Sample constituted reached 188 students with snowball sampling method. The data of the study were collected using the "Questionnaire Form" prepared by the researchers and the "Covid-19 Fear Scale". Data collection tools were applied to the participants electronically via Google Forms.
- Conditions
- Covid-19
- Keywords
- Covid-19, School, Student, Fear, Protective Measure
- Medical subject headings
- COVID-19
What is being measured
The primary outcome is the main question the study is designed to answer.
Covid-19 Fear
Covid-19 Fear Scale: The scale developed by Ahorsu et al. (2020) was adapted to Turkish by Bakioglu, Korkmaz and Ercan (2020). The scale, consisting of seven questions, is a 5-point Likert (1: Strongly disagree, 5: Strongly agree) type. The scale consists of one dimension. The scores that can be obtained from the scale range from 7 to 35. The total score obtained from all items of the scale reflects the level of Covid-19 fear experienced by the individual. A high score means experiencing a high level of fear.
Measured: November-March
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Apr 2021
- Study start12 Nov 2020
- Primary completion30 Mar 2021
- Study completion1 May 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Covid-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 188 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ordu University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hacer Gok Ugur, Ordu University
- Investigators
- Hacer GOK UGUR, Assoc. Prof., Principal investigator, Ordu University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04849611
- Sponsor's protocol ID
- q9wrjg2p
- Status last verified
- Oct 2022
- First submitted
- 22 Mar 2021
- Last updated
- 17 Oct 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH. The Fear of COVID-19 Scale: Development and Initial Validation. Int J Ment Health Addict. 2022;20(3):1537-1545. doi: 10.1007/s11469-020-00270-8. Epub 2020 Mar 27.
PubMed 32226353Bakioglu F, Korkmaz O, Ercan H. Fear of COVID-19 and Positivity: Mediating Role of Intolerance of Uncertainty, Depression, Anxiety, and Stress. Int J Ment Health Addict. 2021;19(6):2369-2382. doi: 10.1007/s11469-020-00331-y. Epub 2020 May 28.
PubMed 32837421
Study at a glance
From the registry record, last updated by the sponsor on 17 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Covid-19 Fear and Compliance With Protective Measures of Students Continuing Face-to-Face Education in the Covid-19 Pandemic Process
- ClinicalTrials.gov ID
- NCT04849611
- Acronym / sponsor ID
- q9wrjg2p
- Conditions
- Covid-19
- Keywords
- Covid-19, School, Student, Fear, Protective Measure
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 188 participants (actual)
- Lead sponsor
- Ordu UniversityUniversity, hospital or other
- Study start
- 12 Nov 2020 (actual)
- Primary completion
- 30 Mar 2021 (actual)
- Study completion
- 1 May 2021 (actual)
- First posted
- 19 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was carried out to determine the fear of Covid-19 and the compliance with protective measures of students who continue their education face-to-face during the covid-19 pandemic process.
Detailed description
The study was carried out descriptively. The study population of a province pandemic period junior ongoing training to face in Turkey. Sample constituted reached 188 students with snowball sampling method. The data of the study were collected using the "Questionnaire Form" prepared by the researchers and the "Covid-19 Fear Scale". Data collection tools were applied to the participants electronically via Google Forms.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 12 to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- continued face-to-face education students
Key inclusion criteria (1 listed)
- Students who volunteered to participate in the study, had their parents' consent, had a web-based smart device, and continued face-to-face education were included.
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Covid-19 Fear
Time frame: November-March
Covid-19 Fear Scale: The scale developed by Ahorsu et al. (2020) was adapted to Turkish by Bakioglu, Korkmaz and Ercan (2020). The scale, consisting of seven questions, is a 5-point Likert (1: Strongly disagree, 5: Strongly agree) type. The scale consists of one dimension. The scores that can be obtained from the scale range from 7 to 35. The total score obtained from all items of the scale reflects the level of Covid-19 fear experienced by the individual. A high score means experiencing a high level of fear.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Oct 2022.
- Background: PubMed 32226353Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH. The Fear of COVID-19 Scale: Development and Initial Validation. Int J Ment Health Addict. 2022;20(3):1537-1545. doi: 10.1007/s11469-020-00270-8. Epub 2020 Mar 27.
- Background: PubMed 32837421Bakioglu F, Korkmaz O, Ercan H. Fear of COVID-19 and Positivity: Mediating Role of Intolerance of Uncertainty, Depression, Anxiety, and Stress. Int J Ment Health Addict. 2021;19(6):2369-2382. doi: 10.1007/s11469-020-00331-y. Epub 2020 May 28.
- Individual participant dataSharing planned: Undecided
Related trials for Covid-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hacer GOK UGUR, Assoc. Prof. principal investigator
Ordu University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid-19, run by Ordu University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Covid-19 Fear (time frame: November-March). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04849611, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Oct 2022.